Check 35,000+ stocks against 26 valuation models and 37 quality factors

Alibaba Health Information Technology Ltd (0241) fair value: what the stock is really worth

As of Sep 24, 2026: fair value of Alibaba Health Information Technology Ltd HK$2.03, price HK$2.83, upside -28.1%, quality 64 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

Fair value above price? No
Good quality? Yes
Add to watchlist

Healthcare · HK · ISIN BMG0171K1018

AH Thin data Sep 24, 2026

Alibaba Health Information Technology Ltd

0241 · HK

Overvalued / MonitorQuality is not strong enough to offset the price risk.

!Fair value HK$2.03 · Overvalued (−28%)

!Quality 64/100

✓Healthy Growth (revenue 5y +17.2 %/yr)

!Thin margins · 5.7% net margin (TTM)

✓Low debt · generates free cash flow

!Mixed vs. peers (6/13)

!Moderate moat 45/100

!Evidence only low, so the estimate is less certain

26 models, one by oneBear HK$1.36 to bull HK$3.07 Growth analysisrevenue history, year by year Quality 64/100 in detail37 factors, each one shown Compared with its peersrank on every measure, side by side

Watch Alibaba Health Information Technology Ltd for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card. Watch for free Pro now: $1 first month

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 24, 2026.

How to read this chart

60‑month range HK$2.61 – HK$21.90 · fair‑value band HK$1.36 – HK$3.07 · the HK$2.83 price screens above the HK$2.03 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 24, 2026.

Follow Alibaba Health Information Technology in your weekly email

Every Wednesday you see whether Alibaba Health Information Technology is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Alibaba Health Information Technology Limited, an investment holding company, engages in the pharmaceutical direct sales, pharmaceutical e-commerce platform, and healthcare and digital services businesses in Mainland China and Hong Kong. The company offers a range of prescription and over-the-counter drugs, nutritional supplements, medical devices, contact lenses, healthcare food, adult and family planning products, and various other health-related products. It also provides medical and healthcare services, including medical checkups, medical consultation, appointment-booking, vaccination, dental and mental care, optometry, and nursing services, as well as traditional chinese medicines. The company provides products and services to business-to-customer and business-to-business customers through offline pharmacy outlets, as well as online stores, such as Tmall, Taobao, Alipay, Ele.me, AMap, DingTalk, Freshippo, and Quark. In addition, it engages in the digital tracking business; asset management; network hospital, software technical services, healthcare related internet information and technical services and research; operation of internet hospitals, as well as Alibaba Health, flagship platform of Alibaba Group for integrated online and offline medical and healthcare resources, providing one-stop healthcare solutions. The company was formerly known as CITIC 21CN Company Limited and changed its name to Alibaba Health Information Technology Limited in September 2014. Alibaba Health Information Technology Limited was incorporated in 1998 and is based in Causeway Bay, Hong Kong.

Stock analysis

Alibaba Health Information Technology Ltd (0241) currently trades at HK$2.83, while our model-based Fair Value estimate is HK$2.03, implying the stock looks roughly 39.2% overvalued today.

Valuation

Bull case: the Growth Earnings group reads highest at a median of HK$5.58 per share, and 9 of the 24 models we run sit above the HK$2.83 price.

Bear case: the Asset-Based group reads lowest at HK$0.7400, and 15 of the 24 models stay below the price. Evidence for this calculation is low.

Scenario range: HK$1.36 (bear) to HK$3.07 (bull), the price of HK$2.83 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 64/100 (solid quality), in the Healthcare sector.

Healthy Growth: Revenue growth appears healthy and is supported by profitability and cash-flow quality.

Alibaba Health Information Technology Ltd reported revenue of HK$34.3B in FY2026 versus HK$20.6B in FY2022, a compound +13.6%/yr. Reported net income was HK$1.9B in FY2026.

Key figures

Market cap HK$49.7B (≈ $6.3B) · P/E ratio 22.0 · P/S ratio 1.24 · EPS (TTM) HK$0.1200 · Net margin 5.7% · Return on equity 11.3% · Return on assets (EBIT) 2.6% · Operating margin 1.7%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 50 out of 100 (medium confidence).

What moves the price

The share trades about 64% below its 52-week high and at its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at 10% fair-value upside, at −28%, 0241 screens richer than that median.

Fair Value models

Bear HK$1.36 Fair Value HK$2.03 Bull HK$3.07

Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2026 figures (about 6 months old). Earnings retained since then (HK$0.0585 per share) are deliberately not added. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.

Highest evidence

FCF DCF HK$1.71 HK$2.45 HK$4.73 75

EPV HK$1.05 HK$1.16 HK$1.26 74

Growth DCF HK$1.63 HK$2.78 HK$4.64 74

All 24 models by family

DCF Models

FCF DCF HK$1.71 HK$2.45 HK$4.73 75

Owner Earnings HK$2.18 HK$4.39 HK$8.86 69

5Y Revenue Exit HK$1.45 HK$2.24 HK$3.88 68

5Y EBITDA Exit HK$1.53 HK$2.40 HK$4.11 71

5Y P/E Exit HK$2.21 HK$4.64 HK$7.99 65

10Y Revenue Exit HK$1.51 HK$2.85 HK$3.69 64

10Y EBITDA Exit HK$1.60 HK$3.02 HK$5.46 63

10Y P/E Exit HK$2.09 HK$4.45 HK$8.38 58

Earnings-Based

Graham-Dodd HK$0.8200 HK$5.69 HK$7.99 61

Lynch FV HK$2.94 HK$4.20 HK$5.46 59

PEG = 1.0 HK$2.94 HK$4.20 HK$5.46 55

EPV HK$1.05 HK$1.16 HK$1.26 74

Multiples

P/E Multiple HK$1.98 HK$2.64 HK$3.30 63

P/S Multiple HK$1.53 HK$2.04 HK$2.55 58

P/B Multiple HK$1.53 HK$2.04 HK$2.55 55

EV/EBIT HK$1.60 HK$2.02 HK$2.43 66

EV/EBITDA HK$1.42 HK$1.77 HK$2.13 67

EV/Revenue HK$1.25 HK$1.63 HK$2.01 54

Asset-Based

NCAV (Graham) HK$0.5500 HK$0.7400 HK$1.10 54

Growth DCF

Growth DCF HK$1.63 HK$2.78 HK$4.64 74

Rev-Margin DCF HK$1.56 HK$2.51 HK$4.48 68

Economic Profit

Residual Income HK$0.9800 HK$1.10 HK$1.92 66

ROIC Compounder HK$1.05 HK$1.26 HK$1.52 70

Growth Earnings

Growth-Adj P/E HK$3.91 HK$5.58 HK$7.25 65

Open the full fair value analysis →

Notify me when 0241 reaches fair value

Put 0241 on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Quality Score breakdown

Overall quality 64/100

Of which business quality 64 · Market factors (momentum, volatility) 14

Profitability 60

Margins and returns on capital today

Quality Growth 56

Are margins and returns improving?

Cashflow 43

Earnings quality: real cash, not paper profit

Fin. Strength 97

Balance sheet, leverage, solvency risk

Investment 85

Disciplined investing over empire-building

Low Volatility 26

Calm price path (market factor)

Momentum 13

Price trend over the last 3–12 months (market factor)

52W Momentum 0

Distance to the 52-week high (market factor)

Net Issuance 47

Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 85/100

Revenue growth appears healthy and is supported by profitability and cash-flow quality.

Revenue growth 1 year

+12.0%

Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.

+8.6%

Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.

+17.2%

Start year 2021 (pandemic). Over 10 years: +89.8% a year

Revenue growth 26 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.

+33.4%

’15

’16

’17

’18

’19

’20

’21

’22

’23

’24

’25

’26

What shareholders gained per year (last 5 years) (mathematically smoothed) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Smoothed = median of all growth paths between the years of the window (trend line on the logarithm of earnings per share): a single extreme year cannot distort the rate. The reported figure stays in the tooltip.

+36.9%

Earnings growth per share plus dividend.

Earnings per share, growth per year+36.9%

Dividend (yield on the price)0.0%

Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.−1% → 5%

2026 sits 91% above its own trend. The rate follows the median trend of the last 5 years, not that single year.

Growth Forecast

A lot of optimism in the price

The price assumes about as much growth as the company has delivered so far and more than analysts expect.

What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).

+19.5%

Yearly growth needed for the next five years to justify today's price.

What forecasts expect ⓘAnalysts publish sales forecasts for the next two fiscal years. For the years after that, growth slows evenly to 2 % a year by year ten (2 % is the long-run rate our models use). Projected years are marked as such.

+9.8%

Yearly sales growth analysts expect, extended to five years.

After inflation (Hong Kong: IMF forecast 2.1% a year to 2030, 1.8% from 2016 to 2025) that is about +17.0% a year for the price and +7.5% for the forecasts.

Forecast 2027 (sales)+12.9%

Forecast 2028 (sales)+10.6%

Projected 2029 (sales)+9.6%

Projected 2030 (sales)+8.5%

Projected 2031 (sales)+7.4%

0241 screens 39% overvalued. Compare with Yifeng Pharmacy Chain Co →

Earlier news

News mood ⓘNews mood, the average tone of recent news (77 articles), rated against how stocks are usually covered. 🚀 Hype = unusually upbeat · 🙂 Positive = above average · 😐 Neutral = typical · 🙁 Negative = below average · 😨 Very negative = unusually downbeat. It reflects the tone of coverage, not our valuation. Neutral

Recent news coverage is roughly neutral, about typical for how stocks are covered.

Burry exits Alibaba, builds large JD.com position over valuation concerns Yahoo Finance · Aug 23, 2026
Meituan, Alibaba Shares Jump as China Seeks to Curb Price Wars Yahoo Finance · Jan 12, 2026

Compare Alibaba Health Information Technology Ltd with another stock

Price, fair value, quality and upside side by side.

First stock

Second stock

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Pharmaceutical Retailers · 61 stocks

Beats the industry median on 5/12 measures

A mixed picture versus its industry peers.

Valuation

Quality Score 64 · Top 25%

Fair Value upside −28% · Below median

Profitability

Return on equity (TTM) 11% · Above median

Return on assets 4% · Above median

Net margin (TTM) 6% · Top 25%

Operating margin (TTM) 2% · Below median

Growth and dividend

Revenue growth 8% · Above median

Valuation Multiplesvs Pharmaceutical Retailers median · lower = cheaper

P/E (TTM) 22.0× · Pricier than median

P/B 2.79× · Pricier than median

P/S (TTM) 1.45× · Priciest 25%

P/FCF 4.6× · Priciest 25%

EV/EBITDA 30.4× · Priciest 25%

Strength profile in five axes (Snowflake)

This stock

Sector peers

VALUE (fair-value potential)0 · sector 33

FUTURE (revenue growth)38 · sector 19

PAST (return on equity)45 · sector 22

HEALTH (low debt)100 · sector 96

DIVIDEND (yield)0 · sector 64

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Pharmaceutical Retailers stocks, each showing price versus our Fair Value estimate.

Stock	Price	Fair Value	vs Fair Value
Yifeng Pharmacy Chain Co 603939	¥22.09	¥40.59	+84%
DaShenLin Pharmaceutical Group 603233	¥17.97	¥26.45	+47%
LBX Pharmacy Chain Joint Stock Company 603883	¥12.90	¥14.19	+10%
MedPlus Health Services Limited MEDPLUS	₹662.00	₹393.38	−41%
Yixintang Pharmaceutical Group 002727	¥10.96	¥9.51	−13%
Anhui Huaren Health Pharmaceutical Co 301408	¥15.56	¥17.12	+10%
ShuYu Civilian Pharmacy Corp 301017	¥12.95	¥5.91	−54%
Apotea AB APOTEA	kr 81.90	kr 46.46	−43%
Luyan Pharma Co 002788	¥11.24	¥15.91	+42%
Cachet Pharmaceutical Co 002462	¥12.40	¥9.94	−20%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks Technology Financial Services Healthcare Consumer Cyclical Consumer Defensive Communication Services Industrials Energy Basic Materials Real Estate Utilities Deeply Undervalued Stocks Undervalued High-Quality Stocks Undervalued Blue-Chip Stocks Undervalued Small-Cap Stocks Undervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark

Run the numbers yourself: free valuation calculators

DCF Calculator Graham Number Peter Lynch Formula DDM Calculator Fama-French Model Intrinsic Value

For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Alibaba Health Information Technology Ltd · Fair Value
HK$2.03 −39%Fair Value
Calculator →

<a href="https://www.fairvalue-calculator.com/stock/0241" target="_blank" rel="nofollow noopener" style="display:inline-flex;align-items:center;gap:12px;box-sizing:border-box;font-family:system-ui,-apple-system,Segoe UI,Roboto,sans-serif;text-decoration:none;background:#0f1814;color:#eaf2ed;border:1px solid #2a3a30;border-radius:12px;padding:12px 16px;max-width:360px"><span style="line-height:1.35"><span style="font-size:12px;color:#9fb0a8">Alibaba Health Information Technology Ltd · Fair Value</span><br><b style="font-size:20px">HK$2.03</b> <span style="color:#e0816f;font-weight:700;font-size:14px">−39%</span></span><span style="font-size:11px;color:var(--fvc-g-mitte);font-weight:700;margin-left:auto;text-align:right;line-height:1.3">Fair&nbsp;Value<br>Calculator&nbsp;→</span></a>

Cite: Fair Value Calculator (2026). "Alibaba Health Information Technology Ltd Fair Value". https://www.fairvalue-calculator.com/stock/0241

Frequently asked questions

Is Alibaba Health Information Technology Ltd (0241) overvalued or undervalued?

As of Sep 24, 2026, our model estimates a fair value of HK$2.03 versus a price of HK$2.83, about −28% upside (overvalued).

What is the fair value of 0241?

Our model-based fair value for Alibaba Health Information Technology Ltd is HK$2.03 (as of Sep 24, 2026), built from audited fundamentals. The current price: HK$2.83.

What is the quality score of 0241?

Alibaba Health Information Technology Ltd has a Quality Score of 64/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.

What is the price target for Alibaba Health Information Technology Ltd (0241)?

Our model-based price target is the fair value of HK$2.03 (as of Sep 24, 2026) from 24 valuation models. Cautious scenario HK$1.36, optimistic scenario HK$3.07. It is a calculation from audited fundamentals, not an analyst target.

What is the Alibaba Health Information Technology Ltd stock forecast for 2026?

Our models put fair value at HK$2.03, about −28% upside versus a price of HK$2.83 (overvalued). Cautious scenario HK$1.36, optimistic scenario HK$3.07. The calculation is refreshed regularly with new filings.

What is the revenue of Alibaba Health Information Technology Ltd (0241)?

Alibaba Health Information Technology Ltd reported trailing-twelve-month revenue of about HK$34.3B (latest available figure, as of Sep 24, 2026).

What growth is priced into Alibaba Health Information Technology Ltd (0241)?

For today's price to be fair in a discounted-cash-flow model, Alibaba Health Information Technology Ltd would have to grow free cash flow by +19.5 % per year for five years (discount rate 11.8 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +17.2 % per year. As of Sep 24, 2026.

What discount rate (WACC) does the fair value of 0241 use?

Our models discount Alibaba Health Information Technology Ltd at 11.8 %: a base by market capitalisation (mid), damped by beta 1.60, country premium for Hong Kong. The same rate applies in all 26 models.

What is a reverse DCF?

A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Alibaba Health Information Technology Ltd that is +19.5 % per year a year over ten years, using the same discount rate (11.8 %) and the same formula as our fair value.

How much growth has Alibaba Health Information Technology Ltd (0241) delivered so far?

Over the past 5 years revenue at Alibaba Health Information Technology Ltd grew +17.2 % a year. The price currently implies +19.5 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.

How fast is the sector of Alibaba Health Information Technology Ltd (0241) growing?

The median revenue growth in the sector is +4.2 % a year. That is the yardstick for the growth priced into Alibaba Health Information Technology Ltd (+19.5 % per year a year): it shows whether the expectation is within the usual range or beyond it.

What is the free cash flow yield of Alibaba Health Information Technology Ltd (0241)?

The free-cash-flow yield on the price is 3.01 %: that much free cash flow Alibaba Health Information Technology Ltd produces per unit of market value. When it exceeds the discount rate of our models (11.8 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.

What is the intrinsic value of Alibaba Health Information Technology Ltd (0241)?

Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Alibaba Health Information Technology Ltd it is HK$2.03 per share (as of Sep 24, 2026), against a price of HK$2.83. It is the blended result of 24 valuation models (cash flow, earnings, asset, dividend).

Is Alibaba Health Information Technology Ltd stock overvalued or undervalued in 2026?

As of Sep 24, 2026, 0241 trades above its calculated fair value: price HK$2.83, fair value HK$2.03, a gap of about −28% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.

Is fair value the same as the market price of 0241?

No. The price is what the market pays today (HK$2.83); the fair value is what the company's own numbers justify (HK$2.03). For Alibaba Health Information Technology Ltd the two are HK$0.7950 per share apart. That gap is exactly why we show both numbers side by side.

How much is Alibaba Health Information Technology Ltd worth?

The market values Alibaba Health Information Technology Ltd at about HK$49.7B (market capitalisation, as of Sep 24, 2026). Per share that is HK$2.83; our models calculate a fair value of HK$2.03 per share.

What do the bullish and bearish scenarios say about 0241?

Our models span a range for Alibaba Health Information Technology Ltd: cautious scenario HK$1.36, base HK$2.03, optimistic HK$3.07 per share (as of Sep 24, 2026, price HK$2.83). The range comes from different growth and margin assumptions, not from analyst opinions.

What is the P/E ratio of 0241?

Alibaba Health Information Technology Ltd trades at a price-to-earnings ratio of 22.0 (as of Sep 24, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of HK$2.03 is built from several models across several years. Other multiples: PEG 0.7, P/B 2.8, P/S 1.5, EV/EBITDA 30.4.

What is the PEG ratio of 0241?

The PEG ratio of Alibaba Health Information Technology Ltd is 0.70 (P/E divided by earnings growth, as of Sep 24, 2026). That is below 1, so growth is priced more cheaply than the earnings multiple alone suggests.

How solid is the balance sheet of Alibaba Health Information Technology Ltd (0241)?

Balance-sheet figures for Alibaba Health Information Technology Ltd (as of Sep 24, 2026): return on equity 11.3%. They feed the Quality Score of 64/100, which measures business quality independently of the share price.

How far is 0241 from its 52-week high?

Alibaba Health Information Technology Ltd trades at HK$2.83, about 64% below its 52-week high of HK$7.78 and at the low of HK$2.83 (as of Sep 24, 2026). Distance from the high says nothing about value: that is what the fair value of HK$2.03 is for.

Which stocks are comparable to Alibaba Health Information Technology Ltd?

From the same area (Healthcare) we also value Yifeng Pharmacy Chain Co, DaShenLin Pharmaceutical Group, LBX Pharmacy Chain Joint Stock Company, MedPlus Health Services Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.

Is Alibaba Health Information Technology Ltd stock attractive at the current price?

The data as of Sep 24, 2026: price HK$2.83, calculated fair value HK$2.03 (−28%), Quality Score 64/100, from 24 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.

How is the fair value of 0241 calculated?

We run Alibaba Health Information Technology Ltd through 24 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of HK$2.03, with the spread shown as a cautious and an optimistic scenario.

Is it still worth investing in stocks now?

The global stock market currently sits 14.0 % above its aggregate fair value. Alibaba Health Information Technology Ltd itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.

What is the share price of Alibaba Health Information Technology Ltd (0241)?

The closing price on Sep 24, 2026 was HK$2.83. Our model-based fair value is HK$2.03, about −28% upside (overvalued). We carry closing prices from our data provider, not a live tick.

What should I pay attention to with Alibaba Health Information Technology Ltd right now?

Solid but not exceptional quality (64/100) and above fair value, neither a clear bargain nor a standout compounder. A fairly wide model range (HK$1.36 to HK$3.07) leaves room in how you read the outcome. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.

Key figures of Alibaba Health Information Technology Ltd

How large is the market capitalisation of Alibaba Health Information Technology Ltd (0241)?

The market capitalisation of Alibaba Health Information Technology Ltd is HK$49.7B (≈ $6.3B). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.

What is the P/S ratio of Alibaba Health Information Technology Ltd (0241)?

The price-to-sales ratio of Alibaba Health Information Technology Ltd is 1.24 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.

What are the earnings per share of Alibaba Health Information Technology Ltd (0241)?

Earnings per share at Alibaba Health Information Technology Ltd are HK$0.1200 (price ÷ EPS = P/E 22.0). Earnings per share over the last twelve months: total profit spread across every single share.

What is the net margin of Alibaba Health Information Technology Ltd (0241)?

The net margin of Alibaba Health Information Technology Ltd is 5.7% (fiscal year 2026). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.

What is the return on equity of Alibaba Health Information Technology Ltd (0241)?

The return on equity (ROE) of Alibaba Health Information Technology Ltd is 11.3% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.

What is the EBIT return on assets of Alibaba Health Information Technology Ltd (0241)?

On an EBIT basis the return on assets of Alibaba Health Information Technology Ltd is 2.6% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.

What is the operating margin of Alibaba Health Information Technology Ltd (0241)?

The operating margin of Alibaba Health Information Technology Ltd is 1.7% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.

How fast is revenue growing at Alibaba Health Information Technology Ltd (0241)?

Revenue at Alibaba Health Information Technology Ltd is growing +7.6% versus a year earlier (3y avg +8.6%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.

How fast are earnings growing at Alibaba Health Information Technology Ltd (0241)?

Earnings per share at Alibaba Health Information Technology Ltd are growing +0.7% versus a year earlier. How much earnings per share grew versus a year earlier.

How much net cash does Alibaba Health Information Technology Ltd (0241) hold?

Alibaba Health Information Technology Ltd holds more cash than debt, HK$5.7B net (fiscal year 2026). The company holds more cash than debt, a safety cushion.

Free · no account needed

Watch Alibaba Health Information Technology Ltd in the live analysis

One click puts Alibaba Health Information Technology Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.